Priovant Therapeutics, Inc.
🇺🇸United States
Clinical Trials
6
Active:1
Completed:2
Trial Phases
3 Phases
Phase 1:1
Phase 2:3
Phase 3:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 2
3 (50.0%)Phase 3
2 (33.3%)Phase 1
1 (16.7%)A Phase 2 Study of the Safety and Efficacy of Brepocitinib in Adults With Cutaneous Sarcoidosis (BEACON)
Phase 2
Recruiting
- Conditions
- Cutaneous Sarcoidosis
- Interventions
- Drug: Oral BrepocitinibDrug: Oral Placebo
- First Posted Date
- 2025-05-18
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Priovant Therapeutics, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT06978725
- Locations
- 🇺🇸
Clinical Trial Site, Madison, Wisconsin, United States
A 12-Week Open-Label Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Skin-Predominant Dermatomyositis
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Priovant Therapeutics, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT06433999
- Locations
- 🇺🇸
Clinical Trial Site, Scottsdale, Arizona, United States
A Phase 3 Study of Brepocitinib in Adults with Active, Non-Infectious, Non-Anterior Uveitis (CLARITY)
Phase 3
Not yet recruiting
- Conditions
- active non-infectious uveitis (intermediate uveitis, posterior uveitis, panuveitis)
- Interventions
- First Posted Date
- 2025-02-25
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Priovant Therapeutics Inc.
- Target Recruit Count
- 105
- Registration Number
- 2024-515089-15-00
- Locations
- 🇦🇹
Johannes Kepler University Linz, Linz, Austria
🇦🇹Medical University Of Vienna, Vienna, Austria
🇧🇪UZ Leuven, Leuven, Belgium
A Study of Brepocitinib in Adults with Active Non-Infectious Non-Anterior Uveitis
Phase 2
Completed
- Conditions
- Non-infectious Pan UveitisNon-infectious Intermediate UveitisNon-infectious Posterior Uveitis
- Interventions
- First Posted Date
- 2022-08-31
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Priovant Therapeutics, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT05523765
- Locations
- 🇺🇸
Clinical Trial Site, Salt Lake City, Utah, United States
A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults with Dermatomyositis
- First Posted Date
- 2022-06-29
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Priovant Therapeutics, Inc.
- Target Recruit Count
- 241
- Registration Number
- NCT05437263
- Locations
- 🇬🇧
Clinical Trial Site, Wolverhampton, United Kingdom
News
No news found